Cystic Fibrosis Therapeutics Market to Post Double-Digit Growth to 2024, Expects iGATE Research in Its Study Available at MarketPublishers.com18 Oct 2017 • by Natalie Aster
LONDON – Today, cystic fibrosis is recognised as one of the most common life-threatening genetic disorders globally.
At present, the US takes lead in the world’s cystic fibrosis therapeutics market. Top 5 EU country markets together grab a share of nearly 20%. Meantime, prevalence of this disease is very low in such Asian countries as India, China and Japan.
Constantly rising prevalence of cystic fibrosis, enhancing awareness about the existing therapeutic options, strong pipeline candidates, ongoing technological progress and high rate of R&D initiatives are amid the key growth engines of the world’s cystic fibrosis market. however, there are also certain growth retraining factors, for example, rising complexity of the disease and high costs associated with treatment.
Between 2017 and 2024, the worldwide cystic fibrosis therapeutics market is projected to see remarkable growth at a double-digit CAGR.
Cutting-edge report “Cystic Fibrosis Therapeutics Market (By Major Marketed Products, Pharmacological Class, & Geography) and Pipeline Analysis – Global Forecast to 2024” by iGATE Research comprises a detailed market analysis, reliable market estimates, a profound assessment of the market segmentation and an insightful overview of the major geographical markets. Moreover, this research publication is an essential source of trustworthy information on the market dynamics, major growth fueling and hampering factors, prevailing trends, emerging challenges and opportunities, competitive landscape, key regulative initiatives, etc. Besides, the report includes in-depth insights into the cystic fibrosis therapeutic pipeline, gives updated sales statistics, reviews the recent developments and product launches, provides comprehensive profiles of the leading companies active in this field. Future forecasts are also at hand.
Major marketed products covered in this report: Ventolin, Orkambi (Lumacaftor/Ivacaftor), Creon, Ibuprofen, Kalydeco (Ivacaftor), Bronchitol (Inhaled Mannitol), Cayston (Inhaled Aztreonam), Zenpep, ADEKplusTM, TOBI/ TOBI Podhaler, Pulmozyme (Dornase Alfa).
A full collection of the publisher’s research studies is offered in the iGATE Research online catalogue at MarketPublishers.com.